[Webinaire] [EN] How to better predict the effect of cancer immunotherapy? Tailored-made humanized mouse models are the key solution!

[Webinar] How to better predict the effect of cancer immunotherapy?

 

Voir la présentation en ligne [Webinaire] [EN] How to better predict the effect of cancer immunotherapy? Tailored-made humanized mouse models are the key solution!

Caroline Mignard, PhD, Study Director
28 Mai 2020
17h00 - [CEST]


The assessment of cancer immunotherapy requires the use of appropriate preclinical animal models that sufficiently reflect the physiological situation in humans.
Oncodesign actively works for your cancer programs through the development of custom-made humanized mouse models: mice co-transplanted with both human tumor and human immune or hematopoietic progenitor cells.
Oncodesign’s scientific teams ran studies on tailored-made humanized immune system (HIS) models to evaluate immunomodulatory agents.
Findings are showing therapeutic efficiency assessed by the monitoring of mice survival and tumor growth.
The impact of therapeutics on tumors and immune cells was assessed by flow cytometry and immunohistochemistry analyses.

Key learning objectives

  • How to custom-made humanized immune system (HIS) models for cancer immunotherapy research
  • Case study & results: evaluation of immuno-onco biologics & demonstration of antitumor effect in HIS model
  • Parameters to consider for HIS model selection
  • Advantages/limitations of each HIS model

About our speaker Caroline Mignard

Caroline Mignard has obtained a Ph.D in Biology from the University of Strasbourg in France and has more than 15 years of experience in preclinical research. As study director at Oncodesign, Caroline has been working closely with our clients to select the most appropriate study designs for the evaluation of their therapies through preclinical studies.
Caroline is also involved in IMODI, (Innovative MODels Initiative) a French consortium dedicated to the development, the characterization and the commercialization of new preclinical models in oncology, including PDX models and humanized mouse models. She is the co-author of several publications about PDX models.

Voir la présentation en ligne  

%MCEPASTEBIN%

 

 

 

[Lettre aux actionnaires] Numéro Avril 2020

24/04/2020

TELECHARGER

[Communiqué de Presse] Création de la nouvelle Business Unit "Intelligence Artificielle" et son nouveau Directeur

20/04/2020

TELECHARGER

[Webinaire] [EN] How to trigger the immune response in anti-tumor therapy? A comprehensive in vitro to in vivo screening platform to identify ICD inducers

[Webinaire] [EN] How to trigger the immune response in anti-tumor therapy? A comprehensive in vitro to in vivo screening platform to identify ICD inducers

Voir la présentation en ligne [Webinaire] [EN] How to trigger the immune response in anti-tumor therapy? A comprehensive in vitro to in vivo screening platform to identify ICD inducers

Akanksha Gangar, PhD, Study Director
28 Avril 2020
17h00 - 17h45  - CEST


Immunological cell death (ICD) is a form of cancer cell death induced by radiotherapy, photodynamic therapy and chemotherapeutic agents.
Unlike apoptosis or necrosis, ICD can induce an effective immune response directed against the tumor whereby both dendritic cells and T lymphocytes are mediators of this response. Dying cancer cells recruit and activate immune cells by releasing damage-associated molecular patterns (DAMPs).

Using our in-house developed screening strategy facilitated by an in vitro platform with four assays, we have identified and characterized several ICD inducers and a Nanocyclix compound for the three key DAMPs and cell viability in several cell lines. Evaluation of phagocytosis and cytokine levels showed that ICD activates both innate and adaptive arms of the immune system. With respect to cancer immunotherapy, the ICD process elicits enhanced adjuvanticity and antigenicity from dying cancer cells and consequently, promotes the development of clinically desired antitumor immunity.

In essence, we describe a novel strategy for the identification of ICD inducers within large chemical libraries followed by ex-vivo co-culture assays to demonstrate enhanced DC and T cell function. 

Key learning objectives 

  • Introduction to ICD
  • How Oncodesign can help you to identify / characterize ICD inducers in vitro, ex vivo and in vivo
  • Case study  

About our speaker Akanksha Gangar 

Akanksha Gangar obtained her PhD in Biochemistry from the prestigious Indian Institute of Science. She then continued as a postdoctoral research associate at the University of North Carolina at Chapel Hill to study cell polarity. In 2005, Akanksha joined INSERM, France as a Research Scientist to work on cell polarity in an oncological context. She joined GSK, France in 2007 to support their drug development in hypertension, diabetes, obesity and oncology. In 2016, Akanksha joined Oncodesign’s in vitro department as a Study director focusing on cancer related projects.

 

 

%MCEPASTEBIN%

Voir la présentation en ligne